KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY).

Cameron R Wolfe, Jonathan Cohen, Kathryn Mahoney, Anna Holmes, Natalia Betancourt, Deepali Gupta, Kazima Tosh, Kristin Narayan, Ed Campanaro, Chloe Katz, Anne-Marie Phelan, Ilker Yalcin, Mark Wingertzahn, Pamela Hawn, Pete Schmidt, Yong Li, Myra Popejoy

Clin Infect Dis 81(3) 439-450

PMID40410927
PMCIDPMC12497959
DOI10.1093/cid/ciaf265
发表日期2025-05-23
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: We report an interim analysis of safety and efficacy of pemivibart in individuals with (cohort A) or without (cohort B) significant immunocompromise in the phase 3 CANOPY trial. METHODS: Eligible participants (aged ≥18 years; negative for current severe acute respiratory syndrome coronavirus 2 infection) received 2 intravenous 4500-mg pemivibart infusions (cohort A) or were randomized 2:1 to receive blinded pemivibart or placebo infusions (cohort B) 90 days apart. Safety was a primary end point for both cohorts. The primary immunobridging end point for cohort A has been reported elsewhere. Composite incidence of reverse-transcription polymerase chain reaction-confirmed symptomatic coronavirus disease 2019 (COVID-19), COVID-19 hospitalization, and all-cause mortality was an exploratory end point. RESULTS: In September-November 2023, 306 participants received pemivibart (cohort A), and 317 received pemivibart and 162 placebo (cohort B). The most common study drug-related adverse events were infusion-related reactions (cohort A: 11 of 306 [3.6%]; cohort B: 7 of 317 [2.2%] for pemivibart and 0 of 162 for placebo). Four of 623 participants (0.6%) who received pemivibart experienced anaphylactic reactions (serious in 2). In cohort A, the composite COVID-19 incidence through month 6 was 11 of 298 (3.7%; 2 deaths). In cohort B, 6 of 317 pemivibart (1.9%; no deaths) and 19 of 160 placebo (11.9%; no deaths) recipients met the end point through month 6 (84.1% standardized relative risk reduction [95% confidence interval, 60.9-93.5; nominal P < .001]), and 15 of 317 pemivibart (4.7%; 1 death) and 29 of 160 placebo (18.1%; no deaths) recipients met the end point through month 12 (73.9% standardized relative risk reduction [52.8-85.6; nominal P < .001]). Twelve-month protection was conferred with no additional dosing. CONCLUSIONS: Pemivibart provided prophylactic efficacy against COVID-19 and was well tolerated by most participants. Anaphylaxis was an important safety risk. CLINICAL TRIALS REGISTRATION: NCT06039449.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2. Cumulative incidence of reverse-transcription polymerase chain reaction (RT-PCR)–confirmed coronavirus disease 2019 (COVID-19), COVID-19–related hospitalization, and all-cause mortality through day 180 for cohort A, the full analysis set. The time to RT-PCR–confirmed symptomatic COVID-19 is calculated as date of event/censoring − date of initial dosing+ 1. Participants who did not have the defined event on or before the above censoring date were censored at the earliest of the end-of-study date, 180-day follow-up, date of participant’s receipt of COVID-19 vaccine, or analysis cutoff date. One participant in cohort A who received a postdose COVID-19 vaccine was censored at the time of vaccination. A second dose of the study drug was administered approximately 90 days after initial dosing.

Cumulative_incidence_of_RT-PCR-confirmed_symptomatic_COVID-19

Time to RT-PCR-confirmed symptomatic COVID-19

Figure 2 · Panel Cumulative_incidence_of_RT-PCR-confirmed_symptomatic_COVID-19

complete 待 EXE 对齐 预期 1 条 已提取 1 条

Panel Cumulative_incidence_of_RT-PCR-confirmed_symptomatic_COVID-19 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Figure 3

Figure 3. Cumulative incidence of reverse-transcription polymerase chain reaction (RT-PCR)–confirmed coronavirus disease 2019 (COVID-19), COVID-19–related hospitalization, and all-cause mortality through day 365 for cohort B, the modified full analysis set, shown through the percentage of COVID-19 test positivity in the United States during the CANOPY study. Abbreviations: CI, confidence interval; HR, hazard risk. Shaded boxes in the top graph represent the overlap of time periods of cohorts A and B in the variant landscape. The time to RT-PCR–confirmed symptomatic COVID-19 was calculated as date of event/censoring − date of randomization + 1. Participants who did not have the defined event on or before the above censoring date were censored at the earliest of the end-of-study date, 365-day follow-up, or analysis cutoff date. The standardized relative risk reduction (RRR) for pemivibart efficacy versus placebo was calculated for cumulative periods through 90, 180, 270, and 365 days, respectively, adjusting for age group (≥55 or < 55 years) as a baseline covariate, using methods detailed by Ge et al [24]. A second dose of study drug was administered approximately 90 days after initial dosing.

Cumulative_incidence_of_RT-PCR_confirmed_symptomatic_COVID-19

Time to RT-PCR–confirmed symptomatic COVID-19

Figure 3 · Panel Cumulative_incidence_of_RT-PCR_confirmed_symptomatic_COVID-19

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Cumulative_incidence_of_RT-PCR_confirmed_symptomatic_COVID-19 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical AbstractGraphical Abstract
非 KM Figure
Figure 1Figure 1. Participant disposition (cohorts A and B). Abbreviations: COVID-19, coronavirus diseases 2019; FAS, full analysis set; mFAS, modified FAS; PK, pharmacokinetic; RT-PCR, reverse-transcription polymerase chain reaction; SAS, safety analysis set. a Represents unique events, not individual people. b The most frequent reasons for not meeting the eligibility criteria were no significant immune compromise or no risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified (n = 13); serious concomitant systemic disease or condition that may lead to hospitalization or death, confound study results, or confer additional risk to participant (n = 7); and prior known or suspected SARS-CoV-2 infection within 120 days before randomization (n = 7). c Reasons for not receiving a full initial dose in cohort A included adverse events (n = 5) and issues related to intravenous line placement (n = 3). d Reasons for not receiving pemivibart in cohort B included participant's request (n = 3) and other (assorted, n = 2). e Reasons for not receiving a full initial dose in cohort B included adverse events (n = 2) and issues related to intravenous line placement (n = 1). f Follow-up is shown through 6 months for cohort A and through 12 months for cohort B.
非 KM Figure